JPH11507541A - 低酸素誘導因子−1および使用方法 - Google Patents
低酸素誘導因子−1および使用方法Info
- Publication number
- JPH11507541A JPH11507541A JP9502264A JP50226497A JPH11507541A JP H11507541 A JPH11507541 A JP H11507541A JP 9502264 A JP9502264 A JP 9502264A JP 50226497 A JP50226497 A JP 50226497A JP H11507541 A JPH11507541 A JP H11507541A
- Authority
- JP
- Japan
- Prior art keywords
- hif
- sequence
- dna
- nucleotide sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.精製されたヒトHIF-1。 2.(a)図10(配列番号1)に示されたDNA配列またはその相補的ストランド; および (b)(a)で規定されたDNA配列に対してストリンジェント条件下で二量化を起 こすDNA配列; によってコードされるヒトHIF-1αポリペプチド。 3.ヒトHIF-1αポリペプチドをコードする単離されたヌクレオチド配列。 4.(a)配列番号1; (b)配列番号1に相補的な核酸配列; (c)少なくとも15個の塩基の長さであり、かつ配列番号1のHIF-1αポリペプチ ドをコードするヌクレオチドに対してストリンジェント条件下で選択的にハイブ リダイズを起こす(a)または(b)の断片; から成る群より選ばれる請求項3の単離されたヌクレオチド配列。 5.前記ヌクレオチドが哺乳類細胞から単離される請求項3のヌクレオチド。 6.前記哺乳類細胞がヒト細胞である請求項5のヌクレオチド。 7.請求項3のヌクレオチドを含む発現ベクター。 8.前記ベクターがプラスミドである請求項7のベクター。 9.前記ベクターがウイルスである請求項7のベクター。 10.請求項7のベクターを用いて安定に形質転換された宿主細胞。 11.前記細胞が原核細胞である請求項10の宿主細胞。 12.前記細胞が真核細胞である請求項10の宿主細胞。 13.HIF-1ポリペプチドまたはHIF-1αポリペプチドまたはそれらの免疫反応性 断片と結合する精製された抗体。 14.前記抗体がポリクロナール抗体である請求項13の抗体。 15.前記抗体がモノクロナール抗体である請求項13の抗体。 16.Hep3B細胞中においてエリトロポイエチン(EPO)、アルドラーゼA(ALDA)、ホ スホグリセリン酸キナーゼ1(PGK1)、ピルビン酸キナーゼM(PKM)、および血管内 皮成長因子(V-EGF)の合成を促進する生物学的活性をもつことができるようにHIF -1αが十分に複製されたアミノ酸配列を有するポリペプチドをコードする精製か つ単離されたヌクレオチド配列。 17.HIF-1βイソ型と二量体を形成するヒトHIF-1α変種ポリペプチドであって 、しかも配列番号2のアミノ酸の少なくとも1つが他のアミノ酸で置換されている 前記ポリペプチド。 18.配列番号4の配列を有するヒト変種HIF-1αポリペプチドをコードする単離 されたヌクレオチド配列。 19.被検者の試料をHIF-1αに結合する試薬と接触させる工程と、該試薬とHIF- 1αとの結合を検出する工程と、を含むHIF-1αの検出方法。 20.前記試薬が配列番号1に相補的なヌクレオチド配列またはその一部分である 請求項19の方法。 21.前記試薬がHIF-1αに特異的な抗体である請求項18の方法。 22.調節領域がHIF-1結合部位を含有する構造遺伝子配列の発現を促進する方法 であって、しかもHIF-1αをコードする治療上有効量のヌクレオチド配列を投与 して該構造遺伝子配列の発現を促進する工程を含む前記方法。 23.前記構造遺伝子配列がEPOをコードする請求項22の方法。 24.前記構造遺伝子配列がVEGFをコードする請求項22の方法。 25.前記構造遺伝子配列が解糖酵素をコードする請求項22の方法。 26.治療の必要な被検者の低酸素関連組織障害を治療する方法であって、しか もHIF-1αをコードする治療上有効量のヌクレオチド配列を投与して組織障害を 実質的に抑制する工程を含む前記方法。 27.治療の必要な被検者の低酸素関連組織障害を治療する方法であって、しか も請求項3のヌクレオチド配列を該被検者の細胞中に導入し、該被検者中で治療 上有効量のHIF-1αを発現させ、かつ組織障害を実質的に抑制する工程を含む前 記方法。 28.調節領域がHIF-1結合部位を含有する構造遺伝子配列の発現を抑制する方法 であって、しかも治療上有効量の抑制ヌクレオチド配列を投与して該構造遺伝子 配列の発現を抑制する工程を含む前記方法。 29.前記抑制ヌクレオチド配列が、HIF-1αをコードするヌクレオチド配列に対 してハイブリダイズを起こす請求項28の方法。 30.HIF-1αをコードする前記ヌクレオチド配列がRNAである請求項29の方法 。 31.HIF-1αをコードする前記ヌクレオチド配列がDNAである請求項29の方法 。 32.前記抑制ヌクレオチド配列がHIF-1α変種ポリペプチドをコードする請求項 28の方法。 33.医薬品として許容しうる担体と治療上有効量のHIF-1とを混合してなる医薬 用組成物。 34.HIF-1αをコードするヌクレオチド配列を医薬品として許容しうる担体中に 含んでなる医薬用組成物。 35.HIF-1α抑制ヌクレオチド配列を医薬品として許容しうる担体中に含んでな る医薬用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/480,473 | 1995-06-06 | ||
US08/480,473 US5882914A (en) | 1995-06-06 | 1995-06-06 | Nucleic acids encoding the hypoxia inducible factor-1 |
PCT/US1996/010251 WO1996039426A1 (en) | 1995-06-06 | 1996-06-06 | Hypoxia inducible factor-1 and method of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008284139A Division JP2009077729A (ja) | 1995-06-06 | 2008-11-05 | 低酸素誘導因子−1および使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11507541A true JPH11507541A (ja) | 1999-07-06 |
Family
ID=23908114
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9502264A Pending JPH11507541A (ja) | 1995-06-06 | 1996-06-06 | 低酸素誘導因子−1および使用方法 |
JP2008284139A Pending JP2009077729A (ja) | 1995-06-06 | 2008-11-05 | 低酸素誘導因子−1および使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008284139A Pending JP2009077729A (ja) | 1995-06-06 | 2008-11-05 | 低酸素誘導因子−1および使用方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US5882914A (ja) |
EP (2) | EP0833840B1 (ja) |
JP (2) | JPH11507541A (ja) |
AT (1) | ATE355299T1 (ja) |
AU (1) | AU704384B2 (ja) |
CA (1) | CA2222279C (ja) |
DE (1) | DE69636936T2 (ja) |
IL (1) | IL118581A (ja) |
WO (1) | WO1996039426A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007512847A (ja) * | 2003-12-03 | 2007-05-24 | アネシヴァ, インコーポレイテッド | Hifオリコヌクレオチドデコイ分子 |
JP2009077729A (ja) * | 1995-06-06 | 2009-04-16 | Johns Hopkins Univ School Of Medicine | 低酸素誘導因子−1および使用方法 |
JP2016514950A (ja) * | 2013-01-25 | 2016-05-26 | エックスセル・バイオサイエンシズ・インコーポレイテッド | 標的細胞の選択的富化のための方法、組成物、キット、及びシステム |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8536998A (en) * | 1997-06-10 | 1998-12-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Regulatory sequences involved in hypoxia regulated gene expression and uses thereof |
US7074895B2 (en) | 1997-08-21 | 2006-07-11 | Quark Biotech, Inc. | Sequences characteristic of hypoxia-regulated gene transcription |
US7973156B2 (en) | 1997-08-21 | 2011-07-05 | Quark Pharmaceuticals Inc. | Hypoxia-regulated genes |
AU9110798A (en) | 1997-08-21 | 1999-03-08 | Quark Biotech, Inc. | Hypoxia-regulated genes |
AU757930B2 (en) | 1997-12-01 | 2003-03-13 | Roche Diagnostics Gmbh | Optimization of cells for endogenous gene activation |
IL136454A0 (en) | 1997-12-04 | 2001-06-14 | Genzyme Corp | Compositions and methods for inducing gene expression |
WO1999048916A2 (en) * | 1998-03-27 | 1999-09-30 | The Board Of Trustees Of The Leland Stanford Jr. University | Hypoxia-inducible human genes, proteins, and uses thereof |
US6124131A (en) * | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
EP1107797A4 (en) * | 1998-08-27 | 2002-10-16 | Quark Biotech Inc | HYPOXIA-REGULATED GENES. |
US6436654B1 (en) * | 1998-11-13 | 2002-08-20 | Pharmacia & Upjohn Ab | Methods for identifying compounds that modulate HIF-1α |
SE9803891D0 (sv) * | 1998-11-13 | 1998-11-13 | Pharmacia & Upjohn Ab | Protein Variants |
WO2000076497A1 (en) * | 1999-06-14 | 2000-12-21 | Cancer Research Ventures Limited | Cancer therapy |
WO2001023426A2 (en) * | 1999-09-30 | 2001-04-05 | Varian Associates, Inc. | Hypoxia-related human genes, proteins, and uses thereof |
FR2801319A1 (fr) * | 1999-11-18 | 2001-05-25 | Inst Nat Sante Rech Med | Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene |
US6893867B1 (en) | 1999-12-23 | 2005-05-17 | Keith A. Webster | Molecular switch for regulating mammalian gene expression |
AU2001233937A1 (en) * | 2000-02-22 | 2001-09-03 | Oxford Biomedica (Uk) Limited | Differential expression screening method |
EP1353946A2 (en) * | 2000-08-07 | 2003-10-22 | Angiogenetics Sweden AB | Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
US7285414B2 (en) * | 2000-09-26 | 2007-10-23 | Emory University | Viruses targeted to hypoxic cells and tissues |
US20040101825A1 (en) * | 2001-09-26 | 2004-05-27 | Van Meir Erwin G. | Viruses targeted to hypoxic cells and tissues |
US7105656B2 (en) * | 2000-10-26 | 2006-09-12 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
US7919274B2 (en) | 2001-03-20 | 2011-04-05 | Dana-Farber Cancer Institute, Inc. | Light-emitting fusion proteins and diagnostic and therapeutic methods therefor |
US6849718B2 (en) * | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
US7176345B2 (en) * | 2001-03-20 | 2007-02-13 | Dana-Farber Cancer Institute, Inc. | Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor |
US6855510B2 (en) * | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
US6660737B2 (en) | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
US6878729B2 (en) | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
CA2447958A1 (en) * | 2001-05-23 | 2002-11-28 | Angiogene Inc. | Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions |
DE60232443D1 (de) * | 2001-06-05 | 2009-07-09 | Masahiro Hiraoka | Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna |
US6838430B2 (en) | 2001-09-28 | 2005-01-04 | The Regents Of The University Of California | Use of HIF-1a variants to accelerate wound healing |
FR2832154B1 (fr) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
WO2003074560A2 (en) * | 2002-03-05 | 2003-09-12 | Angiogenetics Sweden Ab | Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto |
DK2264172T3 (da) | 2002-04-05 | 2017-11-27 | Roche Innovation Ct Copenhagen As | Oligomerforbindelser til modulering af HIF-1á-ekspression |
WO2003087367A2 (en) * | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
NZ520321A (en) * | 2002-07-19 | 2005-03-24 | Auckland Uniservices Ltd | Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
JP5449639B2 (ja) * | 2002-11-01 | 2014-03-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | HIF−1アルファのsiRNA阻害に関する組成物及び方法 |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
EP1583836A4 (en) * | 2002-12-11 | 2006-12-27 | Univ Massachusetts | METHOD OF INTRODUCING siRNA IN ADIPOCYTES |
AU2004207576B8 (en) | 2003-01-28 | 2008-11-20 | Rexahn Pharmaceuticals, Inc. | Antisense oligonucleotides that inhibit expression of HIF-1 |
ES2333794T3 (es) * | 2003-01-31 | 2010-03-01 | Rexahn Pharmaceuticals, Inc. | Oligonucleotidos que inhiben la expresion de hif-1. |
AU2004294950A1 (en) * | 2003-11-26 | 2005-06-16 | Entelos, Inc. | Treatment of rheumatoid arthritis with Hypoxia-Inducible Factor 1alpha antagonists |
US20060003961A1 (en) * | 2004-06-18 | 2006-01-05 | The John Hopkins University | Negative regulation of hypoxia inducible factor 1 by OS-9 |
EP1833840B9 (en) * | 2004-11-09 | 2010-11-10 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a |
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
KR100859506B1 (ko) * | 2005-07-22 | 2008-09-22 | 한국과학기술연구원 | 프롤린 수산화반응에 의한 hif―1 펩타이드와 vbc단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법 |
CN100418574C (zh) * | 2005-10-26 | 2008-09-17 | 王成球 | 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽 |
US20070122448A1 (en) * | 2005-11-28 | 2007-05-31 | Alireza Rezania | Compositions and methods to create a vascularized environment for cellular transplantation |
PT2029742T (pt) | 2006-06-07 | 2016-09-09 | Genzyme Corp | Terapia genética para esclerose lateral amiotrófica e outros transtornos da medula espinal |
ES2390499T3 (es) * | 2006-06-12 | 2012-11-13 | Opko Pharmaceuticals, Llc | Composiciones y métodos para la inhibición de la angiogénesis por sirna |
US20080119433A1 (en) * | 2006-07-06 | 2008-05-22 | Aaron Thomas Tabor | Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
EP3146982B1 (en) | 2006-10-03 | 2019-08-21 | Genzyme Corporation | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
NZ598092A (en) * | 2008-02-14 | 2012-07-27 | Lincoln University | Methods and compositions comprising specific strains of trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth |
SG171952A1 (en) | 2008-12-04 | 2011-07-28 | Opko Ophthalmics Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
EP3421603B1 (en) | 2009-05-02 | 2021-10-06 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
EP4219708A3 (en) | 2009-07-17 | 2023-10-11 | Aaron Thomas Tabor | Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
WO2011109427A2 (en) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
US9446031B2 (en) | 2012-01-18 | 2016-09-20 | National University Of Singapore | Compositions and methods for neovascularization |
ES2868305T3 (es) | 2014-03-28 | 2021-10-21 | Univ Washington Through Its Center For Commercialization | Vacunas contra el cáncer de mama y de ovario |
GB201601527D0 (en) | 2016-01-27 | 2016-03-09 | Univ Southampton | Hif-1 and Hif-2 inhibitors |
US20230212296A1 (en) * | 2020-06-02 | 2023-07-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for treating cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3394040B2 (ja) * | 1989-06-23 | 2003-04-07 | ジェネンテック・インコーポレーテッド | ナトリウム排泄増加性蛋白質受容体bの組成物および合成法および使用法 |
US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
-
1995
- 1995-06-06 US US08/480,473 patent/US5882914A/en not_active Expired - Lifetime
-
1996
- 1996-06-05 IL IL11858196A patent/IL118581A/xx not_active IP Right Cessation
- 1996-06-06 CA CA2222279A patent/CA2222279C/en not_active Expired - Lifetime
- 1996-06-06 JP JP9502264A patent/JPH11507541A/ja active Pending
- 1996-06-06 EP EP96922458A patent/EP0833840B1/en not_active Expired - Lifetime
- 1996-06-06 WO PCT/US1996/010251 patent/WO1996039426A1/en active IP Right Grant
- 1996-06-06 AT AT96922458T patent/ATE355299T1/de not_active IP Right Cessation
- 1996-06-06 AU AU63326/96A patent/AU704384B2/en not_active Ceased
- 1996-06-06 DE DE69636936T patent/DE69636936T2/de not_active Expired - Lifetime
- 1996-06-06 EP EP07000451A patent/EP1806357A1/en not_active Withdrawn
-
1997
- 1997-08-20 US US08/915,213 patent/US6020462A/en not_active Expired - Lifetime
-
1999
- 1999-01-22 US US09/235,217 patent/US6222018B1/en not_active Expired - Lifetime
-
2008
- 2008-11-05 JP JP2008284139A patent/JP2009077729A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009077729A (ja) * | 1995-06-06 | 2009-04-16 | Johns Hopkins Univ School Of Medicine | 低酸素誘導因子−1および使用方法 |
JP2007512847A (ja) * | 2003-12-03 | 2007-05-24 | アネシヴァ, インコーポレイテッド | Hifオリコヌクレオチドデコイ分子 |
JP2016514950A (ja) * | 2013-01-25 | 2016-05-26 | エックスセル・バイオサイエンシズ・インコーポレイテッド | 標的細胞の選択的富化のための方法、組成物、キット、及びシステム |
Also Published As
Publication number | Publication date |
---|---|
US5882914A (en) | 1999-03-16 |
EP0833840A1 (en) | 1998-04-08 |
CA2222279A1 (en) | 1996-12-12 |
US6222018B1 (en) | 2001-04-24 |
JP2009077729A (ja) | 2009-04-16 |
AU704384B2 (en) | 1999-04-22 |
IL118581A (en) | 2000-01-31 |
EP0833840A4 (en) | 2001-12-19 |
DE69636936D1 (de) | 2007-04-12 |
CA2222279C (en) | 2011-02-01 |
EP0833840B1 (en) | 2007-02-28 |
AU6332696A (en) | 1996-12-24 |
EP1806357A1 (en) | 2007-07-11 |
ATE355299T1 (de) | 2006-03-15 |
WO1996039426A1 (en) | 1996-12-12 |
US6020462A (en) | 2000-02-01 |
IL118581A0 (en) | 1996-10-16 |
DE69636936T2 (de) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11507541A (ja) | 低酸素誘導因子−1および使用方法 | |
WO1996039426A9 (en) | Hypoxia inducible factor-1 and method of use | |
Pevsner et al. | n-Sec1: a neural-specific syntaxin-binding protein. | |
Yokoyama et al. | SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene | |
CA2340328C (en) | Stable hypoxia inducible factor-1 alpha and method of use | |
US7501489B2 (en) | cDNAs and proteins involved in hypoxia, circadian and orphan signal transduction pathways, and methods of use | |
US6395548B1 (en) | Methods of modulating of angiogenesis | |
JP2005245469A (ja) | 腫瘍サプレッサ遺伝子、並びに癌の検出、腫瘍進行のモニタおよび癌処置のための方法 | |
AU6131194A (en) | Tata-binding protein associated factors, nucleic acids encoding tafs, and methods of use | |
US5663313A (en) | Human map kinase homolog | |
US6297356B1 (en) | Telomere repeat binding factors and diagnostic and therapeutic use thereof | |
US6077685A (en) | Tumor suppressor merlin and antibodies thereof | |
US5763174A (en) | RNA editing enzyme and methods of use thereof | |
JP4476491B2 (ja) | 新規膜貫通蛋白質をコードする遺伝子 | |
JP4324472B2 (ja) | アトラスチン | |
US6197932B1 (en) | Modulators of actin | |
US6297019B1 (en) | Recombinant polynucleotides encoding CYP7 promoter-binding factors | |
JPH10201491A (ja) | タンパク質ホスファターゼ1結合タンパク質r5 | |
Zhu et al. | Expression of a novel isoform of cyclin I in human testis | |
JP4548938B2 (ja) | Mekk1(セリントレオニンキナーゼ)相互作用性fha(フォークヘッド結合ドメイン)タンパク質1(mif1) | |
US7041497B2 (en) | Nuclear factor κB inducing factor | |
US6995241B1 (en) | Splice variant of head trauma induced cytoplasmatic calcium binding protein | |
JP2001054391A (ja) | 小胞体ストレス転写因子 | |
CZ20014480A3 (cs) | Poraněním hlavy indukovaný cytoplasmatický protein váľící vápník | |
WO1999049043A2 (en) | Human rad17 cell cycle checkpoint |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070803 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071108 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080708 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081105 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090122 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090402 |